false000175942500017594252024-06-052024-06-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2024
__________________________________________
Mirum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
Delaware001-3898183-1281555
(State or other jurisdiction
of incorporation)		(Commission File Number)
(IRS Employer
Identification No.)
989 East Hillsdale Boulevard
Suite 300
Foster City, California
94404
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:(650) 667-4085
950 Tower Lane, Suite 1050
Foster City, California
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
MIRM

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 5, 2024, the Company held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 10, 2024, the record date for the Annual Meeting, 47,118,397 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.
Proposal 1. Election of Directors
The Company’s stockholders elected the three persons listed below as Class II directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:
Votes ForVotes WithheldBroker Non-Votes
Laurent Fischer, M.D.19,162,293 14,762,966 3,790,601 
Patrick Heron24,363,371 9,561,888 3,790,601 
Saira Ramasastry, MS, M.Phil.25,853,444 8,071,815 3,790,601 
Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors (the “Board”) of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows:
Votes ForVotes AgainstAbstentions
37,536,30036,362143,198
Proposal 3. Advisory Vote on Executive Compensation
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement for the Annual Meeting. The final voting results are as follows:
Votes ForVotes AgainstAbstentionsBroker Non-Votes
32,709,2741,125,53290,4533,790,601
Proposal 4. Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation
The Company’s stockholders indicated, on an advisory basis, that the preferred frequency of the stockholder advisory vote on the compensation of the Company’s named executive officers is every one year. The final voting results are as follows:
One YearTwo YearsThree YearsAbstentionsBroker Non-Votes
33,796,38316,06011,772101,0443,790,601
Based upon the foregoing results of Proposal 4, and consistent with the Board’s recommendation, the Board has determined that advisory votes on executive compensation will be submitted to stockholders on an annual basis until the next required vote on the frequency of such votes.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Mirum Pharmaceuticals, Inc.
Date: June 6, 2024By:/s/ Christopher Peetz
Christopher Peetz
Chief Executive Officer

v3.24.1.1.u2
Cover
Jun. 05, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 05, 2024
Entity Registrant Name Mirum Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38981
Entity Tax Identification Number 83-1281555
Entity Address, Address Line One 989 East Hillsdale BoulevardSuite 300
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code (650)
Local Phone Number 667-4085
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol MIRM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001759425
Grafico Azioni Mirum Pharmaceuticals (NASDAQ:MIRM)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Mirum Pharmaceuticals
Grafico Azioni Mirum Pharmaceuticals (NASDAQ:MIRM)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Mirum Pharmaceuticals